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In human cancers, all cancerous cells carry the oncogenic
genetic lesions. However, to elucidate whether cancer is a
stem cell-driven tissue, we have developed a strategy to
limit oncogene expression to the stem cell compartment
in a transgenic mouse setting. Here, we focus on the effects
of the BCR-ABLp210 oncogene, associated with chronic
myeloid leukaemia (CML) in humans. We show that
CML phenotype and biology can be established in mice
by restricting BCR-ABLp210 expression to stem cell anti-
gen 1 (Sca1)
þ cells. The course of the disease in Sca1-BCR-
ABLp210 mice was not modiﬁed on STI571 treatment.
However, BCR-ABLp210-induced CML is reversible
through the unique elimination of the cancer stem cells
(CSCs). Overall, our data show that oncogene expression
in Sca1
þ cells is all that is required to fully reprogramme
it, giving rise to a full-blown, oncogene-speciﬁed tumour
with all its mature cellular diversity, and that elimination
of the CSCs is enough to eradicate the whole tumour.
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Introduction
An axiom in the treatment of tumours is that the remission is,
in general, more difﬁcult to achieve with each relapse.
Despite a better understanding of the biology of tumour
cells, the treatment of most cancers has not signiﬁcantly
changed for the past three decades and the decreasing
mortality has been mostly the result of early detection and
prevention rather than the consequence of effective thera-
peutics (Etzioni et al, 2003; Chabner and Roberts, 2005; Huff
et al, 2006).
A new hypothesis in cancer biology postulates that
tumours are hierarchically structured as abnormal tissues,
which are maintained by cancer stem cells (CSCs) (Reya et al,
2001; Perez-Caro and Sanchez-Garcia, 2006; Dalerba et al,
2007a; Sa ´nchez-Garcı ´a et al, 2007). This theory provides
a rationale to explain the failure of many currently used
antitumoral strategies, because just a small population of
CSCs resistant to the therapy would be enough to maintain
the whole tumour mass (Etzioni et al, 2003; Chabner and
Roberts, 2005; Huff et al, 2006). Evidences supporting this
model have been recently published for human leukaemias
(Bonnet and Dick, 1997; Cobaleda et al, 2000; Cox et al, 2004,
2007; Hope et al, 2004) and solid tumours (Al-Hajj et al, 2003;
Singh et al, 2004; Collins et al, 2005; Kim et al, 2005; Xin et al,
2005; Bao et al, 2006a,b; Dalerba et al, 2007b; Li et al,2 0 0 7 ;
O’Brien et al, 2007; Prince et al, 2007; Ricci-Vitiani et al,
2007). However, this emerging concept has not been fully
validated yet in an experimental model system. If validated,
the CSC hypothesis will have far-reaching consequences for
our understanding of cancer biology and for the development
of new strategies to improve cancer treatment. A major
obstacle to elucidate the contribution that CSCs make to the
development and maintenance of cancer and their suitability
as a target is the lack of a system to limit oncogene expression
to the CSC compartment.
Since the discovery of oncogenes in human tumours, many
efforts have been made to elucidate the causal role that these
oncogenes have in cancer development. These previous
studies have shown that oncogene expression is not only
required for initiation of cancer but also for the maintenance
of the disease (Chin et al, 1999; Huettner et al, 2000; Boxer
et al, 2004). In mouse models where oncogene expression is
driven by tissue-speciﬁc promoters, tumours arise at high
frequency, but disappear again when the inducing stimulus is
switched off (Chin et al, 1999; Huettner et al, 2000; Boxer
et al, 2004). However, it has not been biologically proven that
cancer is a hierarchically organized tissue that can be created
and maintained similar to a normal stem cell-based tissue.
If that is indeed the case, then cancer should be created and
maintained similarly to any other normal stem cell-driven
tissue, similar to the haematopoietic system. In a normal
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8stem cell-driven tissue, genetic programming of stem cells is
all that is required to (re)constitute all differentiated cells
forming the tissue and the genetic information responsible for
the stem cell programming is not present anymore within the
differentiated cells that form the tissue. Thus, we reasoned
that a similar organization could be happening for cancer
formation.
To address these biological questions, we have used the
BCR-ABLp210 oncogene associated with chronic myeloid
leukaemia (CML) in humans as a model (Koefﬂer and
Golde, 1981; Melo and Barnes, 2007). CML is a paradigmatic
stem cell disorder that begins as a protracted chronic phase,
characterized by high leukocyte counts and enlarged spleen
and liver. In all patients, the chronic phase of CML eventually
converts to a blast crisis that is indistinguishable from acute
leukaemia. The speciﬁc BCR-ABL inhibitor STI571 can pro-
long the remission times of CML patients because it is able to
eliminate the BCR-ABL-expressing differentiated cells that
constitute the bulk of the tumour (Druker et al, 2001).
However, it cannot eliminate BCR-ABL-expressing CSCs,
even though it can penetrate into the cells, and these CSCs
eventually repopulate the tumour with STI571-resistant ma-
ture cells (Graham et al, 2002; Hu et al, 2006; Primo et al,
2006; Jiang et al, 2007).
Here, we show that CML phenotype and biology can
be established in mice in which we limited BCR-ABLp210
expression to stem cell antigen 1 (Sca1)
þ cells. These model
mice mimic CML human pathology. The course of the CML
disease in the Sca1-BCR-ABLp210 mice was not modiﬁed on
STI571 treatment. However, we show that BCR-ABLp210-
induced CML is reversible through the unique elimination
of the CSCs. To our knowledge, this study demonstrates for
the ﬁrst time that limited oncogene expression in CSCs is all
that is required to fully reprogramme it, giving rise to a full-
blown, oncogene-speciﬁed tumour with all its mature cellular
diversity, and that CSC elimination is enough to eradicate the
whole tumour.
Results
Derivation of Sca1-BCR-ABLp210 mice
The mouse Ly-6E.1 promoter (Miles et al, 1997) was used to
drive Sca1-directed expression of a human BCR-ABLp210
(Sca1-BCR-ABLp210) or TK-IRES-BCR-ABLp210 transgene
(Sca1-TK-IRES-BCR-ABLp210) in C57BL/6 CBA mice
(Figure 1). This promoter is known to have heterologous
expression in haematopoietic stem cells (HSCs) (Miles et al,
1997), hence transgene expression is restricted to a limited
percentage of Sca1-expressing cells. The BCR-ABLp210-over-
expressing animals had normal gestation and were viable.
Three independent lines were obtained and used to examine
the phenotype further (Table I). As c-kit is known from earlier
studies to be downregulated in leukaemia stem cells (Blair
and Sutherland, 2000; Neering et al, 2007), our functional
deﬁnition of stem cell in this study does not include c-kit as a
surface marker. Quantitative RT–PCR of BCR-ABLp210 and/or
TK messenger mRNA conﬁrmed that expression was largely
conﬁned to Sca1
þ cells with little or no ectopic expression in
Sca1
  cells (Figure 1). In line with these results, neither BCR-
ABL protein nor downstream signalling was detected in
Sca1
 Lin
þ cells of Sca1-BCR-ABLp210 mice (Supplementary
Figure 1 online). As reported earlier in transgenic reporter
lines with the same promoter (Miles et al, 1997; Ma et al,
2002a,b), BCR-ABLp210 was expressed in a limited percen-
tage of Sca1
þ cells (25–50%) as measured by single-cell
RT–PCR (Supplementary Figure 2 online). This enables
cell transformation to occur in a similar manner as it happens
in humans, where cells expressing the oncogene are present
along with non-expressing cells. The phenotype described
here is therefore due primarily to the expression of BCR-
ABLp210 in Sca1
þ cells.
CML development in Sca1-BCR-ABLp210 mice
The expression of BCR-ABLp210 in Sca1
þ cells led to sig-
niﬁcant increases in the numbers of white blood cells (WBCs)
and in the percentages of neutrophils (Table I) in the periph-
eral blood (PB) of Sca1-BCR-ABLp210 animals (Figure 2A).
Flow cytometry of bone marrow (BM) cells demonstrated
signiﬁcantly increased numbers of cells staining positively for
the myeloid markers Gr1 and Mac-1, comprising up to
75–90% of the cells in the BM of transgenic animals
(Figure 2A). However, the percentage of Sca1
þLin
  cells in
BM did not increase (data not shown), similarly as it happens
in human CML (Jamieson et al, 2004). Macroscopic analysis
of these animals showed splenomegaly (Table I) and hepato-
megaly (79% of the animals). The histologic examination of
the spleen and liver demonstrated the presence of megakar-
yocytes as markers of myeloid metaplasia (Figure 2B) and
expansion of the splenic red pulp by predominantly granulo-
cytic myeloid cells (Figure 2C). This was conﬁrmed by ﬂow
cytometric analysis (Figure 2A). In addition, inﬁltration of
myeloid cells was also seen in the liver, lymph nodes and
lung (Figure 2C). The major cause of death in animals that
had progressive disease was related to myeloid inﬁltration of
extramedullary organs and kidney failure (30%), or the
evidence for progression to blast crisis (70%). In addition,
targeting Sca1
þ cells in non-haematopoietic tissues gave rise
to carcinoma development (lung adenocarcinoma 10%, he-
patocarcinoma 3%, GIST 2%, osteogenic sarcoma 2% and
Sertoli cell tumour 2%; data not shown). Altogether, the
survival time of mice expressing BCR-ABLp210 in Sca1
þ
cells ranged from 4 to 18 months (Figure 1E; Table I). Mice
surviving myeloid inﬁltration of extramedullary organs pro-
gressed spontaneously to a blast crisis characterized by the
appearance of blasts (myeloid or lymphoid) in PB, BM,
spleen and liver (Figure 2D and E). Similar to the human
disease, this secondary disorder appeared in the context of a
myeloproliferative disease (Figure 2F). The time of transition
to blast crisis has been described to be reduced with in-
creased levels of BCR-ABL in human CML cells (Melo and
Barnes, 2007; Modi et al, 2007). Similarly, when compound
Sca1-BCR-ABLp210 transgenic mice were generated
(Figure 1), leukaemia was detectable at 1–2 months of age
(Figure 1; Table I). Thus, the limited expression of BCR-
ABLp210 to Sca1
þ cells is able to mimic human CML,
characterized also by a progression from chronic towards
an acute phase (blast crisis), which is also invariably fatal in
Sca1-BCR-ABLp210 mice and that is dependent on the dose of
the oncogene expression in the Sca1
þ cells.
The fusion protein responsible for CML has been shown to
cause genome instability in humans (Giehl et al, 2005; Melo
and Barnes, 2007). We examined Sca1-BCR-ABLp210 mice for
evidence of secondary genetic changes. First, we examined
the overall DNA methylation status in tumour cells of
Stem cell-driven cancer
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cytosine to give qualitative information on nuclear distribu-
tion. We performed similar analyses in human CD34
þ CML
cells. Although control cells present unmethylated DNA, an
aberrant DNA methylation pattern was observed in tumour
cells of human CML (n¼3) and Sca1-BCR-ABLp210 mice
(n¼8) (see Supplementary Figure 3 online). As genetic
instability and centrosome defects are common and early
detectable features in CML (Melo and Barnes, 2007), we
sought to investigate whether centrosome aberrations occur
in Sca1-BCR-ABLp210 mice. We examined 14 CML samples
including Sca1
þ cells of 9 newly diagnosed mice (chronic
phase) and 5 blast crisis specimens by using a centrosome-
speciﬁc antibody to pericentrin. Centrosome abnormalities
were detected in 23.6±5.1% of chronic phase cells and in
61.6±5.3% of blast crisis cells, but in only 3.1±0.9% of
controls (see Supplementary Figure 3 online). The similarities
between the secondary genetic changes observed in humans
and Sca1-BCR-ABLp210 mice suggest that similar mechan-
isms contribute to CML progression in both species.
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Figure 1 Sca1-BCR-ABLp210 and Sca1-TK-IRES-BCR-ABLp210: transgene constructs, expression and survival. (A) Schematic representation of
the genomic structure of the mouse Sca1 locus and the Sca1-BCR-ABLp210 and Sca1-TK-IRES-BCR-ABLp210 transgenic vectors used in this
study. The HSV-TK/BCR-ABLp210 fusion gene construct is a bicistronic construct consisting of the herpes simplex thymidine kinase (TK) cDNA
separated from BCR-ABLp210 by the picornaviral internal ribosome entry site (IRES) sequence. NotI sites used to excise the transgene fragments
and EcoRI sites used to examine Southern blots are indicated. (B) Identiﬁcation of the transgenic mice by Southern blot analysis of tail snip
DNA after EcoRI digestion. Human ABL cDNA was used for the detection of the transgene. Sca1-BCR-ABLp210 and the endogenous c-Abl are
indicated. Lines IS1A and IS1B are two different Sca1-BCR-ABLp210 transgenic lines. (C) Quantiﬁcation of BCR-ABLp210 expression in Sca1-
BCR-ABLp210 mice and quantiﬁcation of thymidine kinase (TK) and BCR-ABLp210 expression in Sca1-TK-IRES-BCR-ABLp210 mice by real-time
PCR in Sca1
þLin
  and Sca1
 Lin
þ cells. Percentage of TK and BCR-ABLp210 transcripts with reference to b-actin is shown. (D) Quantiﬁcation
of BCR-ABLp210 expression by real-time PCR in Sca1
þLin
  cells of Sca1-BCR-ABLp210 mice (line IS1A or IS1B) and of double Sca1-BCR-
ABLp210 mice (line IS1A IS1B). (E) Kaplan–Meier survival plots of Sca1-BCR-ABLp210 mice (line IS1A or IS1B), double Sca1-BCR-ABLp210
mice (line IS1A IS1B) and Sca1-TK-IRES-BCR-ABLp210 mice (line IS9A). The total number of mice analysed in each group is indicated.
Statistical analysis was performed using the w
2 test, and the corresponding P-values are given in parentheses.
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We next examined the nature of the leukaemogenic cell in the
Sca1-BCR-ABLp210 model. To determine whether the
Sca1
þLin
  population contains CSC, we sorted Sca1
þLin
 
and Sca1
 Lin
þ cells from mice that developed CML.
Transplantation of puriﬁed fractions of cells into sublethally
irradiated syngeneic recipient mice was used to assess leu-
kaemogenesis in vivo. Each of the mice transplanted with
Sca1
þ Lin
  cells developed CML that was phenotypically
identical to the primary disease (Table II). Importantly,
Sca1
 Lin
þ cells did not show leukaemic engraftment into
secondary recipients or induced leukaemia, even at 10 times
higher concentrations. Overall, these data indicate that the
CSCs reside in the Sca1
þ cell compartment. All these facts
indicate that restricting oncogene expression to the stem cell
compartment is sufﬁcient to generate all the CML cell types,
including the most differentiated ones, which do not express
the oncogene and are unable to propagate the disease.
Characterization of CSCs in Sca1-BCR-ABLp210 mice
Having prospectively puriﬁed a population highly enriched
for CSC, we used gene expression to identify the genes that
are associated with BCR-ABLp210 reprogramming of stem
cells (Supplementary Table I online; Figure 3). We performed
a supervised analysis of the transcriptional proﬁles of CSCs
puriﬁed from Sca1-BCR-ABLp210 versus those from control
mice. The data showed that a total of 293 genes are repro-
ducibly regulated in Sca1-BCR-ABLp210 versus control HSC
with a false discovery rate (FDR) p0.07% (Supplementary
Table I online). Human CML has been characterized earlier
according to gene expression proﬁle (Kronenwett et al, 2005).
Remarkably, the gene expression patterns of Sca1
þLin
  cells
from Sca1-BCR-ABLp210 mice were similar to those from the
human CML CD34
þ cells (Figure 3A), thereby further vali-
dating the model by reﬂecting the similarities in the tran-
scriptome between the two populations. Thus, BCR-ABLp210-
dependent, stem cell-driven murine CML shares the molecu-
lar features of human CML.
The CSC hypothesis represents a modern-day interpreta-
tion of the proposal made by Rudolph Virchow and Julius
Cohnheim that cancer results from the activation of dormant
embryonal-rest cells (Virchow, 1855; Cohnheim, 1867).
Accordingly, we next proceeded to examine, in CSCs from
Scal-BCR-ABLp210 mice, the expression of embryonic surface
markers, the presence of which has been identiﬁed earlier in
undifferentiated mouse embryonic stem cells (Nunomura
et al, 2005) (Figure 3B). We could identify reproducible
upregulation of gene signals corresponding to 55 embryonic
stem cell surface proteins in the CSCs from Sca1-BCR-
ABLp210 mice (FDR p1%). These results show that CSCs
in Sca1-BCR-ABLp210 present embryonic ﬁgures that could
represent attractive targets for selective CSC removal.
STI571 treatment does not modify the survival of
Sca1-BCR-ABLp210 mice
We also examined the effect of STI571 treatment in Sca1-BCR-
ABLp210 mice. STI571 treatment began 1 day after leukaemia
was conﬁrmed by PB analysis. Mice were monitored clini-
cally and by serial PB count for evidence of leukaemia.
STI571 did not prolong the survival of these mice
(Figure 4A) and Sca1-BCR-ABLp210 mice treated with
STI571 did not demonstrate a marked reduction in WBC
and spleen weight (Figure 4B). This idea is in agreement
with the insensitivity of the human leukaemic stem cells to
STI571 (Graham et al, 2002; Hu et al, 2006; Primo et al, 2006;
Jiang et al, 2007). Thus, we next examined whether CSCs
from STI571-treated Sca1-BCR-ABLp210 mice propagates
CML disease to secondary recipients. Equal numbers of
Sca1
þLin
  cells (5 10
3) from the BM of STI571-treated
animals failing therapy were used to reconstitute sublethally
irradiated recipients. All reconstituted animals (n¼5) devel-
oped CML disease with an average latency of only 24 days,
conﬁrming that persistent BCR-ABLp210 expression is not
required to maintain the malignant phenotype of CML CSCs.
CSC ablation eradicates CML in Sca1-BCR-ABLp210
mice
We next examined whether CSC ablation implies elimination
of CML in vivo following tumour formation in a whole
animal. For this purpose, we generated Sca1-TK-IRES-BCR-
ABLp210 mice. These animals developed disease similarly to
the Sca1-BCR-ABLp210 ones (Figure 1; Table I). Diseased
Sca1-TK-IRES-BCR-ABLp210 mice were injected daily with
ganciclovir (GCV) as described in the Materials and methods
section. During this period, mice were monitored for evi-
dence of leukaemia. GCV treatment clearly reduced the
number of mice developing tumours (Figure 5A), with the
majority of animals demonstrating a marked reduction in
splenomegaly and, in some cases, complete normalization of
their peripheral WBC (Figure 5B) and lack of solid tumours
(although we could not conﬁrm their presence before treat-
Table I Incidence and age of CML onset in Sca1-BCR-ABLp210 and Sca1-TK-IRES-BCR-ABLp210 mice
Transgenic line Mice
autopsied
a
Mice with
tumour
(%)
b
Age in months
at tumour
onset
Haematopoietic
tumour type
(%)
WBC/ml,
neutrophils (%)
Hgb
(g/100ml)
Spleen
weight
(mg)
IS1A (Sca1-BCR-ABLp210) 34 34 (100) 8–12 CML–BC (100) 12900±1750 (43±4) 11.5±1.3 285±36
IS1B (Sca1-BCR-ABLp210) 25 25 (100) 4–10 CML–BC (100) 11850±1650 (38±5) 12.7±1.1 217±29
IS1A+IS1B 10 10 (100) 1–2 Leukaemia ND 13.2±1.3 ND
IS9A (Sca1-TK-IRES-BCR-ABLp210) 23 23 (100) 6–10 CML–BC (100) 13300±230 (41±8) 11.1±1.2 261±23
ND, not determined.
aNumber of mice during or after the period of cancer.
bNumber of mice with CML and percentage of tumour incidence. Normal range of WBC counts was 4000–10000/ml. Mean neutrophil
percentage of control animals was 10±4% WBCs, and the neutrophil percentage in control animals did not exceed 20%. Thus, neutrophilia is
deﬁned as more than 20% neutrophils. Hgb indicates haemoglobin (normal range, 12–16g/100ml). Normal spleen weight in control animals is
78–92mg (n¼25). The WCC estimations were made when the mice were premorbid. CML–BC indicates mice spontaneously progress to blast
crisis. Po0.001 for Sca1-BCR-ABLp210 mice versus control mice.
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transgenic animals. Although all animals exhibited a pro-
longed survival with GCV treatment, approximately 23% of
the animals died of leukaemia during the treatment with the
drug. To test the possibility that CSCs would remain within
Sca1-TK-IRES-BCR-ABLp210 mice after GCV treatment, we
highly puriﬁed the Sca1
þLin
  sub-population from BM and
transplanted it into sublethally irradiated syngeneic recipi-
ents (n¼5). Sca1
þLin
  cells did not show leukaemic en-
graftment into secondary recipients or induced leukaemia,
indicating that leukaemogenic cells had been removed from
this population by the GCV treatment. To our knowledge, this
study demonstrates for the ﬁrst time that killing CSCs is an
effective therapeutic strategy for cancer treatment.
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Figure 2 Sca1-driven BCR-ABLp210 expression induces CML. (A) Cells from PB of Sca1-BCR-ABLp210 mice were analysed by ﬂow cytometry.
Representative FACS analysis demonstrating accumulation of mature myeloid cells in PB and spleen, and an increase in the myeloid fraction
within BM. PB, peripheral blood; BM, bone marrow. (B) Representative histologic appearance of liver and spleen of diseased Sca1-BCR-
ABLp210 mice after haematoxylin–eosin staining. Megakaryocytes in spleen and liver deﬁne myeloid metaplasia and are indicated by arrows.
(C) Organ inﬁltration by myeloid cells. Haematoxylin–eosin-stained sections of the spleen (megakaryocytes, myeloid blasts and mature
myeloid cells), liver (perivascular inﬁltration of the liver by blasts and mature myeloid cells), peritoneal lymph node (with myeloid metaplasia)
and lung (inﬁltration of the lung by blasts and mature myeloid cells). (D) Phenotypic characteristics of cells from peripheral blood (PB) as
determined by ﬂow cytometry. Blast cells but not mature granulocytes are present in PB from two different leukaemic Sca1-BCR-ABLp210 mice.
Note that the B-cell leukaemia is characterized by the presence of blast cells co-expressing Mac-1 and B220. (E) Liver haematoxylin–eosin-
stained sections showing blast inﬁltration and histologic appearance of blood smears (Giemsa staining) in Sca1-BCR-ABLp210 mice in blast
crisis. Blast cells inﬁltrate both liver and PB. (F) Representative histologic appearance of liver and spleen tissue sections stained by Masson’s
trichrome of Sca1-BCR-ABLp210 mice in blast crisis. The presence of ﬁbrosis (green colour) and blast inﬁltration in the liver and the spleen of
Sca1-BCR-ABLp210 mice demonstrate that the blast crisis takes place in the context of a myeloproliferative disease.
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The elucidation of the molecular mechanisms that underlie
tumour development not only remains a tremendous chal-
lenge for basic science but also represents an essential step in
the development of new and more potent drugs, in particular
with the emergence of cancer-speciﬁc, targeted therapies. The
origin of human cancer within a particular tissue is often
impossible to determine, due to the advanced stages of many
tumours when patients enter the clinic. Our knowledge about
Table II CML disease is readily transplantable to secondary recipients
Sorted cells Number of
transplanted cells
Transplanted
animals
Incidence of
CML (%)
Latency of disease
(days±s.d.)
Sca1
+Lin
  (BM, Sca1-BCR-ABLp210 mice) 10.000 8 100 69±14
1.000 8 100 85±11
Sca1
+Lin
  (BM, control mice) 10.000 8 0 NA
1.000 8 0 NA
Sca1
 Lin
+ (BM, Sca1-BCR-ABLp210 mice) 1 10
5 80 N A
1 10
6 80 N A
Sca1
 Lin
+ (BM, control mice) 1 10
5 80 N A
1 10
6 80 N A
NA, not applicable.
Eight irradiated syngenic recipients mice per cohort were transplanted with the indicated number of cells. The diagnosis of CML was conﬁrmed
by histological and immunophenotypic examination of the ill recipient mice.
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Figure 2 Continued.
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therefore derived from animal models that recapitulate
human disease as accurately as possible. In contrast to the
situation in humans, the genotype–phenotype correlations
found in human cancer processes (where a given cancer-
inducing event usually associates speciﬁcally with a given
type of cancer) have not always been established in mouse
models of cancer. This phenotypic variability is most likely to
be related to the fact that the generation of current mouse
models of cancer has only taken into account the genetic
defects identiﬁed in human cancers without taking into
account where the initiating mutation occurred. An emerging
concept in tumour biology suggests that tumours are main-
tained by CSCs (Reya et al, 2001; Perez-Caro and Sanchez-
Garcia, 2006; Dalerba et al, 2007a). However, it has not been
biologically proven that cancer is formed and maintained
similar to a normal stem cell-based tissue. In a normal stem
cell-driven tissue, genetic programming of stem cells is all
that is required to (re)constitute all differentiated cells form-
ing the tissue and the genetic information responsible for the
stem cell programming is not present anymore within the
differentiated cells that form the tissue. Thus, we reasoned
that a similar organization could be happening for cancer
formation. To overcome these limitations and create a tract-
able model to study the contribution of CSCs to cancer
development and maintenance, we have generated a trans-
genic mouse model in which oncogene expression is limited
to Sca1
þ cells in mice. As a universally accepted model of
human stem cell disorder, we focused our studies on the BCR-
ABLp210 oncogene associated with CML in humans (Melo
and Barnes, 2007). This Sca1-BCR-ABLp210 model was able
to reproduce genetically and physiologically the human CML,
providing a unique opportunity, both for the identiﬁcation of
mechanisms contributing to the myeloproliferative disease
and the progression to blast crisis, and ultimately to design
effective therapies to interfere with these molecular events
AB
Figure 3 Identity of cancer stem cells in Sca1-BCR-ABLp210 mice. To identify genes associated with BCR-ABLp210-induced reprogramming of
stem cells, we have compared the gene expression proﬁles of puriﬁed CSC populations versus normal HSCs. Both CSCs and HSCs were isolated
as Sca1
þLin
  cells. (A) Comparison of the mouse and human CSCs at the molecular level. Graphical description of the expression pattern in
CSCs (Sca1
þLin
  cells) from BM (n¼10) and PB (n¼7) of Sca1-BCR-ABLp210 mice of genes that have been previously published to be
signiﬁcantly regulated in the human CML CD34
þ fraction (Kronenwett et al, 2005). The genes were similarly regulated in CSCs of Sca1-BCR-
ABLp210 mice. We referred the ratios of the CSCs to the control haematopoietic stem cells (Sca1
þLin
  cells puriﬁed from control mice). Green
indicates that the genes are downregulated in CSCs versus HSCs and red indicates upregulation. Green asterisks mark genes that are
downregulated in human CD34
þ CML. The remaining genes behave similarly in both human and mouse stem cells. (B) Embryonic surface
proteins in CSCs of Scal-BCR-ABLp210 mice. Graphical description of the expression pattern in CSCs (Sca1
þLin
  cells) from BM (n¼12) of
Sca1-BCR-ABLp210 mice of previously identiﬁed upregulated cell surface markers in undifferentiated mouse embryonic stem cells (Nunomura
et al, 2005). We identiﬁed genes for which signal intensities were upregulated (threshold±2) in CSCs and in at least seven CSC samples. We
referred the ratios of the CSCs to the control haematopoietic stem cells (Sca1
þLin
  cells puriﬁed from control mice). Each gene (identiﬁed at
right) is represented by a single row of coloured boxes; each experimental mouse is represented by a single column. Data are displayed by
a colour code. Red ﬁelds indicate higher values than the median, green ﬁelds indicate lower values than the median.
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Figure 4 STI571 treatment in Sca1-BCR-ABLp210 mice. (A) STI571 treatment does not modify the survival of Sca1-BCR-ABLp210 mice. Mice
were randomized to treatment with either STI571 or placebo to study the in vivo efﬁcacy in three independent experiments. The survival curve
depicts the percentage of animals alive at the indicated time point. The number of mice in each arm (n) is also shown. (B) Sca1-BCR-ABLp210
mice treated with STI571 do not demonstrate a marked reduction in white blood count and spleen weight. Standard errors are depicted. *The
data depicted are from mice in (A) and are representative of at least three independent experiments.
B
Sca1-TK-IRES-BCR-ABLp210 mice treated with GCV show a marked reduction in white blood count and spleen weight. 
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Figure 5 GCV treatment in Sca1-TK-IRES-BCR-ABLp210 mice. (A) Survival of Sca1-TK-IRES-BCR-ABLp210 mice following GCVadministration.
Diseased Sca1-TK-IRES-BCR-ALp210 mice were randomized to treatment with either GCV injected daily or placebo (saline solution treatment)
to address the question of whether selective ablation of Sca1
þ cells can be used as a therapeutic target in cancer. The survival curve depicts the
percentage of animals alive at the indicated time point. The number of mice in each arm (n) is also shown and corresponds to three
independent experiments. Po0.0001 for treated versus untreated animals. (B) Sca1-TK-IRES-BCR-ABLp210 mice treated with GCV show
a marked reduction in white blood count and spleen weight. Standard errors are depicted. *The data depicted are from mice in (A) and are
representative of at least three independent experiments.
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and maintenance.
From the point of view of the basic understanding, the
demonstration that cancer development can be established in
mice by limiting oncogene expression to Sca1
þ cells ques-
tions our view of the early steps of carcinogenesis. Results
presented here suggest that the oncogene imposes a gene
regulatory state in stem cells that somehow persists during
haematopoiesis and which imposes a tumour phenotype
reﬂective of the usual CML that cannot be modiﬁed through
oncogene inactivation, an observation that could be applied
to other cancer-initiating gene defects (Figure 6). This fact
also brings up the distinction between the direct conse-
quences of expression of oncogenic BCR-ABL, such as
engagement of signalling pathways that require ongoing
BCR-ABLp210 protein expression and will cease with subse-
quent differentiation of Sca1
þ stem cells and the indirect
consequences of BCR-ABLp210 activity such as DNA methy-
lation, centrosome abnormalities (or aneuploidy subsequent
to abnormal centrosome function) or other secondary genetic
A
B
d
d c m o
t c
t c
Figure 6 Generation of stem cell-driven cancer in the mouse. (A) In human pathologies and in most animal models of cancer, the oncogenic
alteration(s) is(are) present in all the cellular types that compose the tumoral tissue, from the cancer stem cells to the more differentiated types.
(B) In our stem cell-driven cancer model, the expression of the oncogenic alteration is restricted to the progenitor compartment but is
nevertheless capable of generating a full-blown tumour with all its differentiated cellular components. This model implicitly relies on the fact
that the oncogenic presence in the cancer stem cell compartment originates (epi)genetic latent alterations, which are responsible for the
posterior appearance of the tumoral phenotype. These alterations are represented here as repressing (red) or activating (green) marks in the
chromosome, induced by the oncogene in the CSCs and inherited in the lower compartments where the oncogene is no longer expressed, so
that these descendant cells are not normal and constitute a non-clonogenic leukaemic progeny.
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regardless of continued BCR-ABLp210 expression. Our ﬁnd-
ings show that BCR-ABL appears to cause epigenetic and/or
genetic changes in tumour-maintaining cells that could render
them insensitive to BCR-ABL inactivation. Thus, BCR-ABL
oncogene inactivation cannot change this epigenetic/genetic
context in differentiated tumour cells in agreement with the
common occurrence of tumour relapse by which tumours
evolve to escape oncogene dependence. Therefore, we hy-
pothesize that BCR-ABL mediates tumorigenesis through epi-
genetic/genetic modiﬁcation of target genes that remain in
this modiﬁed state in the mature tumour even in the absence
of BCR-ABL. As an added level of complexity, this effect of
BCR-ABL in stem cells could be mediated by a kinase-inde-
pendent mechanism and therefore it would be Gleevec in-
sensitive. The model provides evidence that the oncogenic
proteins expressed in stem/progenitor cells can have selective
impacts that depend on their intrinsic molecular properties.
This result in turn provides a rationale for the striking
associations between different chromosome translocations,
unique fusion genes and cancer phenotypes. Importantly, a
small subset of mice developed additional solid tumours,
indicating that BCR-ABL stem cell-driven oncogenesis is not
only speciﬁc to haematopoietic tissues but also represents a
broader mechanism for deregulation of stem cell differentia-
tion, providing a paradigm that can be applied to solid-organ
cancers. Thus, these results support the view of cancer as a
disease of cell differentiation rather than multiplication, ask-
ing for a redeﬁnition of the role of oncogenes.
Overall, our ﬁndings indicate that BCR-ABLp210 appears to
reprogramme stem cells rendering them insensitive to poster-
ior BCR-ABLp210 inactivation. This evidence that BCR-
ABLp210 inactivation could not stop tumour growth is in
apparent conﬂict with earlier studies showing that BCR-
ABLp210 is required for the persistence of tumoral character-
istics in cellular systems (Szczylik et al, 1991; Choo et al,
1994; Skorski et al, 1994; Cobaleda and Sanchez-Garcia,
2000; Huettner et al, 2000). However, we should consider
that the effects of BCR-ABLp210 inactivation will depend on
the mechanisms by which BCR-ABLp210 is actually contribut-
ing to the tumorigenic phenotype, which are likely to vary
according to the genetic and cellular context. When BCR-
ABLp210 causes CML in vivo, as described here and observed
in humans, its inactivation cannot eliminate CML cell pro-
genitors. By contrast, when BCR-ABLp210 is just transforming
a cell line into tumorigenic, its inactivation would result in
tumour regression (Szczylik et al, 1991; Choo et al, 1994;
Skorski et al, 1994; Cobaleda and Sanchez-Garcia, 2000;
Huettner et al, 2000). So, as mentioned before, it is very
possible that the molecular mechanisms of action of BCR-
ABLp210 at the CSC level are different from those acting at
later stages of tumoral cell differentiation (i.e. direct versus
indirect BCR-ABL effects as discussed above).
The data presented here further show for the ﬁrst time the
in vivo physiological relevance of the CSC suppression using
a model system representing in vivo biology of the human
CML disease. Speciﬁc CSC ablation is able to eradicate CML
in our model, although these cells were insensitive to
Gleevec-mediated BCR-ABLp210 inactivation, suggesting
that the reprogramming imposed by BCR-ABLp210 renders
the cells oncogene independent. We conclude that limited
oncogene expression in a CSC is all that is required to fully
reprogramme it, giving rise to a full-blown, oncogene-speci-
ﬁed tumour with all its mature cellular diversity, and that
BCR-ABLp210-induced CML is reversible through the unique
elimination of the CSC. Further experiments should conﬁrm
that this observation could be applied to other cancer-initiat-
ing gene defects. However, are there targets that can be
exploited to eradicate CSCs without affecting healthy stem
cells? The characterization of the CSCs in the Sca1-BCR-
ABLp210 mice showed that CSCs were different from normal
stem cells exhibiting cell surface embryonic ﬁgures that could
be used to target CSCs. Thus, in agreement with earlier
studies (Yilmaz et al, 2006; Liu et al, 2007; Ito et al, 2008),
these data provide a rationale for the development of diag-
nostic and therapeutic strategies targeting CSCs without
affecting normal stem cells. The hope is to translate this
discovery into new tools for a better diagnostic and thera-
peutic management of the human disease.
Materials and methods
Generation of transgenic mice and BM transplantation
The Ly-6E.1 gene has been shown earlier to direct heterologous
gene expression in HSCs of the adult BM and to specify copy
number-dependent and integration site-independent expression
(Miles et al, 1997). In this study, we have exploited the fact that
this transgene is not expressed in all Sca1-positive cells for the study
of cancer. The Sca1-BCR-ABLp210 and Sca1-TK-IRES-BCR-ABLp210
vectors were generated as follows. The 6kb EcoRI–EcoRI fragment,
containing the human BCR-ABLp210 cDNA, and the 9kb EcoRI–
EcoRI TK-IRES-BCR-ABLp210 cassette were inserted into the ClaI
site of the pLy6 vector (Miles et al, 1997), resulting in Sca1-BCR-
ABLp210 and Sca1-TK-IRES-BCR-ABLp210 vectors, respectively. The
transgene fragments (Figure 1A) were excised from its vectors by
restriction digestion with NotI, puriﬁed for injection (2ng/ml) and
injected into CBA C57BL/6J fertilized eggs. Transgenic mice were
identiﬁed by Southern blot analysis of tail snip DNA after EcoRI
digestion. Human ABL cDNA was used for detection of the
transgene. A total of 82 transgenic animals and 25 control animals
were used to deﬁne the phenotype. Three independent transgenic
lines were generated and analysed and similar phenotypic features
were seen in both Sca1-BCR-ABLp210 lines and Sca1-TK-IRES-BCR-
ABLp210 mice. IS1A line was crossed with IS1B transgenic mice to
generate compound heterozygotes and increase BCR-ABL dosage
(Figure 1B and D).
To determine the nature of the leukaemogenic cell, Sca1
þLin
 
and Sca1
 Lin
þ cells were isolated and highly puriﬁed from the BM
of a leukaemic primary mouse before or after different treatments or
from control mice. The sorting purity of these cells was re-analysed
with the ﬂuorescence-activated cell sorting (FACS) and determined
to be over 98%. In each cohort, these cells were injected
intravenously into sublethally irradiated (4Gy) recipient mice.
Diseased mice were killed and assessed for leukaemia development.
Mice that did not develop disease within 20 weeks post-
transplantation were killed and tested for engraftment.
Histological analysis
All mice included in this study were subjected to standard necropsy.
All major organs were examined under the dissecting microscope,
and samples of each organ were processed into parafﬁn, sectioned
and examined histologically. All tissue samples were taken from
homogenous and viable portions of the resected sample by the
pathologist and ﬁxed within 2–5min of excision. Haematoxylin–
eosin-stained sections of each tissue were reviewed by a single
pathologist (TF). Demonstration of ﬁbrosis in spleen and liver of
diseased Sca1-BCR-ABLp210 mice (green colour) was carried out by
Masson’s trichrome staining. For comparative studies, age-matched
mice were used.
Analysis and monitoring of disease
PB was collected from retro-orbital plexus with a heparinized
capillary tube, and total WBC and differential counts were
performed twice a week. The number of WBCs was determined
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RCLB lysis buffer (0.15M NH4Cl; 1mM KHCO3; 0.1mM Na2-EDTA,
pH 7.4).
Flow cytometry
Nucleated cells were obtained from total BM (ﬂushing from the long
bones), PB, thymus, liver and spleen. To prepare the cells for ﬂow
cytometry, contaminating red blood cells were lysed with RCLB
lysis buffer and the remaining cells were then washed in PBS with
2% fetal calf serum (FCS). After staining, all cells were washed once
in PBS with 2% FCS containing 2mg/ml propidium iodide (PI) to
allow dead cells to be excluded from both analyses and sorting
procedures. Monoclonal antibodies were obtained from Pharmin-
gen and included: lineage markers (CD45R/B220, for B lineage
staining; CD4, CD8 and CD3 for T-cell lineage; CD11b and Gr1 for
myeloid lineage and TER119 for erythroid lineage) and Sca1 (E13-
161.7) for stem cells. Single cell suspensions from the different
tissue samples obtained by routine techniques were incubated ﬁrst
with puriﬁed anti-mouse CD32/CD16 (Pharmingen) prior to the
addition of other antibodies, to block binding through Fc receptors
and then with an appropriate dilution of the different antibodies at
room temperature or 41C, respectively. The samples and the data
were analysed in a FACSCalibur using CellQuest software (Becton
Dickinson). Speciﬁc ﬂuorescence of FITC and PE excited at 488nm
(0.4W) and 633nm (30mW), respectively, as well as known
forward and orthogonal light scattering properties of mouse cells
were used to establish gates. For each analysis, a total of at least
5.000 viable (PI ) cells were assessed.
Cell puriﬁcation
For cell sorter separation, BM cells were incubated with anti-Sca1
and anti-lineage marker antibodies (CD3, CD4, CD8, B220, TER119,
Gr1 and Mac-1). Sca1
þLin
  and Sca1
 Lin
þ cells were isolated and
highly puriﬁed from the BM of leukaemic primary mice or control
mice by FACS (FACSVANTAGE; Becton Dickinson). c-kit (CD117)
was not used for stem cell isolation, as earlier studies of human and
mouse specimens have described downregulation of c-kit as a
feature of leukaemia stem cells (Blair and Sutherland, 2000;
Neering et al, 2007). Sorted cells were then re-analysed for purity
with the FACS and determined to be over 98%.
RNA extraction
Total RNAwas isolated in two steps using TRIzol (Life Technologies
Inc., Grand Island, NY) followed by RNeasy Mini-kit (Qiagen Inc.,
Valencia, CA) puriﬁcation following the manufacturer’s RNA clean-
up protocol with the optional On-column DNase treatment. The
integrity and the quality of RNA were veriﬁed by electrophoresis
and its concentration was measured.
Lineal RNA ampliﬁcation
T-7-based RNA ampliﬁcations and preparations of cDNA probes
were performed. Brieﬂy, a maximum amount of 5mg of total RNA
was converted to double-stranded cDNA using the superscript
choice system (Life Technologies Inc.) using oligo-dT primer
containing a T7 RNA polymerase promoter. The double-stranded
cDNA was cleaned up, and T7 in vitro transcription was performed
using Megascript T7 in vitro transcription kit (Ambion, Austin, TX)
following the manufacturers’ instructions.
Microarray procedures
Second round ampliﬁed RNA (2.5mg) from each sample was
directly labelled with cyanine 3 (Cy3)-conjugated dUTP, whereas
2.5mg of second round ampliﬁed RNA from the Universal Mouse
Reference RNA (Stratagene) was labelled with cyanine 5 (Cy5)-
conjugated dUTP as a reference. For all the microarray studies, the
CNIO MouseChip was used and hybridizations were performed as
described (Bermejo-Rodriguez et al, 2006). After washing, the slides
were scanned using a Scanarray 5000 XL (GSI Lumonics Kanata,
Ontario, Canada) and images were analysed with the GenePix 4.0
program (Axon Instruments Inc., Union City, CA).
Data analysis
Data obtained from each hybridization were stored in a database for
analysis. The Cy3/Cy5 ratios were normalized to the median ratio
value of all of the spots in the array. After normalization, spots with
intensities for both channels (sum of medians) less than that of the
local background were discarded. The ratios of the remaining spots
were log transformed (base 2), and duplicated spots on the
MouseChip were averaged to the median. To obtain the expression
proﬁle of CSCs (Sca1
þLin
  cells puriﬁed from Sca1-BCR-ABLp210
mice), we referred the ratios of the CSCs to the control HSCs
(Sca1
þLin
  cells puriﬁed from control mice).
Real-time PCR quantiﬁcation
cDNA for use in quantitative PCR studies was synthesized using
reverse transcriptase (Access RT–PCR System; Promega, Madison,
WI). Second round ampliﬁed RNA (2ml) was transcribed. Primers
and probes used for quantitative PCR are commercially available
(TaqMan Assays-on-Demand Gene Expression Products; Applied
Biosystems, Foster City, CA). In addition, the probes were designed
so that genomic DNA would not be detected during the PCR. The
sequences of the speciﬁc primers and probes were as follows: BCR-
ABL
p210, sense primer 50-TTCTGAATGTCATCGTCCACTCA-30, anti-
sense primer 50-AGATGCTACTGGCCGCTGA-30 and probe 50-CCAC
TGGATTTAAGCAGAGTTCAAAAGCCC-30; c-Abl, sense primer
50-CACTCTCAGCATCACTAAAGGTGAA-30, antisense primer 50-CGTTT
GGGCTTCACACCATT-30 and probe 50-CCGGGTCTTGGGTTATAAT
CACAATG-30.
Immunolocalization of 5mC and pericentrin
Human and mouse cells grown on coverslips were stained with
DAPI (blue) and mouse monoclonal antibodies against 5mC (red)
(kindly provided by Alain Niveleau, Universite Claude Bernard,
Lyon, France) as described earlier (Habib et al, 1999). Images of the
nuclear immunolocalization of 5mC were obtained in a Leica
DMRA ﬂuorescence microscope coupled to a Leica DC200 digital
camera and captured with the Adobe Photoshop software. Control
and Sca1-BCR-ABLp210 Sca1
þ cells were stained with antibodies
against pericentrin (green; Berkeley ref. PRB-432C) to label
centrosomes and with DAPI (blue) to label nuclei.
STI571 (Gleevec)
STI571 treatment regimens were based on earlier pharmacokinetic
studies of STI in BCR-ABL tumour-bearing mice (le Coutre et al,
1999; Druker et al, 2001; Perez-Caro et al, 2007). Effectivity of BCR-
ABLp210 suppression by STI571 was conﬁrmed by assaying the
survival of Ba/F3 cells expressing BCR-ABLp210 24h after STI571
treatment and by the treatment of BCR-ABL transgenic mice
according to previously published studies (Perez-Caro et al, 2007)
(data not shown). For the animal studies, stock solutions of 5 and
10mg/ml were prepared fresh in water, sterile ﬁltered and
administered to mice in a volume of 250ml by gavage twice a day.
Mice were started on STI571 or placebo (the same volume of diluent
water) beginning 1 day after leukaemia was conﬁrmed (day 0) by
means of an STI571 regimen of 50mg/kg every morning and
100mg/kg every evening by gavage. STI571 was administered in a
volume of 250ml sterile water by means of straight or curved animal
feeding needles. Mice tolerated the therapy well and no interruption
of therapy was necessary. Mice were followed clinically three times
a week, and periodic PB counts were obtained by tail vein blood
draw as indicated. For the survival analysis portion of this study,
the death end point was determined either by spontaneous death of
the animal or by elective killing of the animal because of signs of
pain or suffering according to established criteria.
GCV treatment
Sca1-TK-IRES-BCR-ABLp210 mice were used to test the effectiveness
of GCV-induced cell in CSCs that express BCR-ABL. Expression of
TK induces conversion of the prodrug nucleoside GCV to its drug
form as a phosphorylated base analogue. The phosphorylated GCV
is incorporated into the DNA of replicating cells causing irreversible
arrest at the G2/M checkpoint followed by apoptosis (Rubsam et al,
1998). GCV, after preliminary testing, was administered at a dose of
100mg/kg/day by i.p. injection for 14 days. This dose has been
reported to kill cells expressing TK in transgenic mice (Bush et al,
1998). Dosing started when the mice were leukaemic. A control
group was given injections of normal saline.
Statistical analysis
The w
2 test was used to compare leukaemia incidence in Sca1-BCR-
ABLp210 mice versus control mice. Signiﬁcance analysis of
microarrays proposed by Tusher et al (2001) was used to assess
statistical signiﬁcance of our differentially expressed genes.
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Western blot analysis of BCR-ABLp210 expression and presence of
phospho-CrkL (Tyr207) was carried out in Sca1
 Lin
þ cells of
control and Sca1-BCR-ABLp210 mice. Tyr207 in CrkL is the BCR-ABL
phosphorylation site. As positive controls, we used the following
cell lines: Ba/F3, a murine haematopoietic precursor IL-3-depen-
dent cell line (Palacios and Steinmetz, 1985), Ba/F3þBCR-
ABLp210, a Ba/F3 cell line expressing human BCR-ABLp210
(Sa ´nchez-Garcı ´a and Gru ¨tz, 1995), and K562 cells that were the
ﬁrst human immortalized myelogenous cell line to be established
derived from a 53-year-old female CML patient in blast crisis
(Lozzio and Lozzio, 1975). All cells were maintained in DMEM with
10% FCS. When required, 5% of WEHI-3B-conditioned medium
was included as a source of IL-3. Extracts were normalized for
protein content by Bradford analysis (Bio-Rad Laboratories Inc.,
Melville, NY, USA) and Coommasie blue gel staining. Lysates were
run on a 10% SDS–PAGE gel and transferred to a PVDF membrane.
After blocking, the membrane was probed with the following
primary antibodies: BCR (Ab-2) (Oncogene Science), Phospho-CrkL
(Tyr207) (Cell Signaling) and actin (I-19; Santa Cruz Biotechnol-
ogy). Reactive bands were detected with an ECL system (Amer-
sham).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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